{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:17:41Z","timestamp":1772165861419,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["220866\/Z\/20\/Z"],"award-info":[{"award-number":["220866\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["220866\/Z\/20\/Z"],"award-info":[{"award-number":["220866\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["220866\/Z\/20\/Z"],"award-info":[{"award-number":["220866\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["220866\/Z\/20\/Z"],"award-info":[{"award-number":["220866\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["220866\/Z\/20\/Z"],"award-info":[{"award-number":["220866\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["220866\/Z\/20\/Z"],"award-info":[{"award-number":["220866\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["220866\/Z\/20\/Z"],"award-info":[{"award-number":["220866\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["220866\/Z\/20\/Z"],"award-info":[{"award-number":["220866\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["220866\/Z\/20\/Z"],"award-info":[{"award-number":["220866\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["220866\/Z\/20\/Z"],"award-info":[{"award-number":["220866\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["220866\/Z\/20\/Z"],"award-info":[{"award-number":["220866\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["220866\/Z\/20\/Z"],"award-info":[{"award-number":["220866\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["220866\/Z\/20\/Z"],"award-info":[{"award-number":["220866\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["220866\/Z\/20\/Z"],"award-info":[{"award-number":["220866\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["220866\/Z\/20\/Z"],"award-info":[{"award-number":["220866\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["220866\/Z\/20\/Z"],"award-info":[{"award-number":["220866\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["220866\/Z\/20\/Z"],"award-info":[{"award-number":["220866\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["220866\/Z\/20\/Z"],"award-info":[{"award-number":["220866\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pakistan has one of the highest burdens of Hepatitis C virus (HCV) infection globally. To achieve the World Health Organization\u2019s goals for HCV elimination, there is a need for substantial scale-up in testing, treatment, and a reduction in new infections. Data on the population impact of scaling up treatment is not available in Pakistan, nor is there reliable data on the incidence of infection\/reinfection. This project will fill this gap by providing important empirical data on the incidence of infection (primary and reinfection) in Pakistan. Then, by using this data in epidemic models, the study will determine whether response rates achieved with affordable therapies (sofosbuvir plus daclatasvir) will be sufficient to eliminate HCV in Pakistan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective multi-centre cohort study will screen 25,000 individuals for HCV antibody (Ab) and RNA (if Ab-positive) at various centers in Pakistan- Karachi (Sindh) and Punjab, providing estimates of the disease prevalence. HCV positive patients will be treated with sofosbuvir and daclatasvir for 12-weeks, (extended to 24-weeks in those with cirrhosis) and the proportion responding to this first-line treatment estimated. Patients who test HCV Ab negative will be recalled 12\u00a0months later to test for new HCV infections, providing estimates of the incidence rate. Patients diagnosed with HCV (~\u20094,000) will be treated and tested for Sustained Virological Response (SVR). Questionnaires to assess risk factors, productivity, health care usage and quality of life will be completed at both the initial screening and at 12-month follow-up, allowing mathematical modelling and economic analysis to assess the current treatment strategies. Viral resistance will be analysed and patients who have successfully completed treatment will be retested 12\u00a0months later to estimate the rate of re-infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The HepFREEPak study will provide evidence on the efficacy of available and widely used treatment options in Pakistan. It will also provide data on the incidence rate of primary infections and re-infections. Data on incidence risk factors will allow us to model and incorporate heterogeneity of risk and how that affects screening and treatment strategies. These data will identify any gaps in current test-and-treat programs to achieve HCV elimination in Pakistan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study registration<\/jats:title>\n                    <jats:p>This study was registered on clinicaltrials.gov (NCT04943588) on June 29, 2021.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-023-17290-3","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T05:02:47Z","timestamp":1702875767000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HepFREEPak: protocol for a multi-centre, prospective observational study examining efficacy and impact of current therapies for the treatment of hepatitis C in Pakistan and reporting resistance to antiviral drugs: study protocol"],"prefix":"10.1186","volume":"23","author":[{"given":"Ambreen","family":"Arif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliya","family":"Hasnain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Auj","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Asim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Nabeel","family":"Shafqat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abeer","family":"Altaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor","family":"Saba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Polychronis","family":"Kemos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Azim","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vickerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huma","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asad Ali","family":"Choudhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad Khalid","family":"Niaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham R.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naheed","family":"Choudhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"key":"17290_CR1","unstructured":"Seth Nelson M, Yusuf AM. Hepatitis C is on the rise: centracare \u2013 family health clinic; 2022 . Available from: https:\/\/www.centracare.com\/blog\/2022\/august\/hepatitis-c-is-on-therise\/#:~:text=There%20are%20more%20than%2058,hepatitis%20B%20and%20hepatitis%20C. (Accessed 18 Apr 2023)."},{"issue":"4","key":"17290_CR2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/jvh.13802","volume":"30","author":"E Mooneyhan","year":"2023","unstructured":"Mooneyhan E, Qureshi H, Mahmood H, Tariq M, Maqbool NA, Anwar M, et al. Hepatitis C prevalence and elimination planning in Pakistan, a bottom-up approach accounting for provincial variation. J Viral Hepat. 2023;30(4):345\u201354.","journal-title":"J Viral Hepat"},{"key":"17290_CR3","unstructured":"APEX Consulting. Final report \u2013 population based prevalence survey of hepatitis B&C Punjab, 2018. Bureau of Statistics Planning and Development Board, Government of Pakistan; 2019. 2018 Available from: https:\/\/www.globalhep.org\/sites\/default\/files\/content\/news\/files\/202206\/Pakistan%20National%20Hepatitis%20Elimination%20Profile-FINAL.pdf.(Accessed 04 May 2023)."},{"key":"17290_CR4","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021. Towards ending viral hepatitis 2016. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/246177.(Accessed 18 Apr 2023)."},{"key":"17290_CR5","unstructured":"National Hepatitis Elimination Profile for Pakistan: Key Takeaways: Coalition for Global Hepatitis Elimination. Available from: https:\/\/www.globalhep.org\/news\/national-hepatitis-elimination-profile-pakistan-key-takeaways. (Accessed 1 Aug 2023)."},{"issue":"8","key":"17290_CR6","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1097\/MEG.0000000000001376","volume":"31","author":"S Sarwar","year":"2019","unstructured":"Sarwar S, Tarique S, Aleem A, Khan AA. Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan. Eur J Gastroenterol Hepatol. 2019;31(8):1035\u20139.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"17290_CR7","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/s12882-019-1631-4","volume":"20","author":"SUR Cheema","year":"2019","unstructured":"Cheema SUR, Rehman MS, Hussain G, Cheema SS, Gilani N. Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial. BMC Nephrol. 2019;20(1):438.","journal-title":"BMC Nephrol"},{"issue":"7","key":"17290_CR8","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.12669\/pjms.37.7.4627","volume":"37","author":"N Butt","year":"2021","unstructured":"Butt N, Anoshia, Khan MA, Akbar A. Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An experience of tertiary care hospital in Karachi. Pak J Med Sci. 2021;37(7):2014\u20139.","journal-title":"Pak J Med Sci."},{"issue":"5","key":"17290_CR9","first-page":"e38833","volume":"15","author":"AS Rahman","year":"2023","unstructured":"Rahman AS, Amir M, Jamal Q, Riaz M, Fareed K, Siddiqui M. End treatment response and sustained viral response in patients with hepatitis C virus receiving sofosbuvir and daclatasvir. Cureus. 2023;15(5):e38833.","journal-title":"Cureus"},{"issue":"1","key":"17290_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jceh.2017.06.003","volume":"8","author":"V Mehta","year":"2018","unstructured":"Mehta V, Mahajan R, Midha V, Narang V, Kaur K, Singh A, et al. Impact of direct acting antiviral therapy for treatment of hepatitis C genotypes 1, 3 and 4: a real life experience from India. J Clin Exp Hepatol. 2018;8(1):7\u201314.","journal-title":"J Clin Exp Hepatol"},{"issue":"4","key":"17290_CR11","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/hep.27726","volume":"61","author":"DR Nelson","year":"2015","unstructured":"Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127\u201335.","journal-title":"Hepatology"},{"issue":"1","key":"17290_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.12669\/pjms.331.12163","volume":"33","author":"S Sarwar","year":"2017","unstructured":"Sarwar S, Khan AA. Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: is there difference? Pak J Med Sci. 2017;33(1):37\u201341.","journal-title":"Pak J Med Sci"},{"key":"17290_CR13","doi-asserted-by":"publisher","first-page":"550205","DOI":"10.3389\/fphar.2020.550205","volume":"11","author":"S Mushtaq","year":"2020","unstructured":"Mushtaq S, Akhter TS, Khan A, Sohail A, Khan A, Manzoor S. Efficacy and safety of generic sofosbuvir plus daclatasvir and sofosbuvir\/velpatasvir in HCV genotype 3-infected patients: real-world outcomes from Pakistan. Front Pharmacol. 2020;11:550205.","journal-title":"Front Pharmacol"},{"issue":"4","key":"17290_CR14","doi-asserted-by":"publisher","first-page":"e0175562","DOI":"10.1371\/journal.pone.0175562","volume":"12","author":"YA Capileno","year":"2017","unstructured":"Capileno YA, Van den Bergh R, Donchunk D, Hinderaker SG, Hamid S, Auat R, et al. Management of chronic hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan. PLoS ONE. 2017;12(4):e0175562.","journal-title":"PLoS ONE"},{"issue":"4","key":"17290_CR15","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1053\/j.gastro.2018.06.042","volume":"155","author":"R Esteban","year":"2018","unstructured":"Esteban R, Pineda JA, Calleja JL, Casado M, Rodriguez M, Turnes J, et al. Efficacy of Sofosbuvir and Velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis. Gastroenterology. 2018;155(4):1120\u20137 e4.","journal-title":"Gastroenterology."},{"issue":"3","key":"17290_CR16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1053\/j.gastro.2019.05.007","volume":"157","author":"PAC Wing","year":"2019","unstructured":"Wing PAC, Jones M, Cheung M, DaSilva S, Bamford C, Jason Lee WY, et al. Amino acid substitutions in genotype 3a hepatitis C virus polymerase protein affect responses to Sofosbuvir. Gastroenterology. 2019;157(3):692\u2013704 e9.","journal-title":"Gastroenterology."},{"issue":"2","key":"17290_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"17290_CR18","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.","journal-title":"J Biomed Inform"},{"issue":"3","key":"17290_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"G EuroQol","year":"1990","unstructured":"EuroQol G. EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","journal-title":"Health Policy"},{"issue":"3","key":"17290_CR20","first-page":"282","volume":"29","author":"S Manolakopoulos","year":"2016","unstructured":"Manolakopoulos S, Zacharakis G, Zissis M, Giannakopoulos V. Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C. Ann Gastroenterol. 2016;29(3):282\u201396.","journal-title":"Ann Gastroenterol"},{"issue":"4","key":"17290_CR21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","volume":"8","author":"F Cui","year":"2023","unstructured":"Cui F, Blach S, Manzengo Mingiedi C, Gonzalez MA, Sabry Alaama A, Mozalevskis A, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023;8(4):332\u201342.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"17290_CR22","unstructured":"World Health Organization. Combating hepatitis B and C to reach elimination by 2030: advocacy brief: World Health Organization.; 2016. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/206453. (Accessed 2 Sep 2023)."}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-17290-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-023-17290-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-17290-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T21:03:13Z","timestamp":1703019793000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-023-17290-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["17290"],"URL":"https:\/\/doi.org\/10.1186\/s12889-023-17290-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3324435\/v1","asserted-by":"object"}]},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,18]]},"assertion":[{"value":"4 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is being conducted in accordance with the UK Policy Framework for Health and Social Care Research.This study was reviewed and approved by the Queen Mary Ethics Review Committee (Reference number QMERC20.306) on 27th May 2021, the Institutional Review Board of Aga Khan University (Reference number: 2021\u20136341-18329) on 29th June 2021 and Dow University of Health Sciences (Approval number: 2139\/DUHS\/Approval\/2021\/463) on June 12th 2021. The study was approved by the National Bioethics Committee (NBC) Pakistan (Ref: No.4\u201387\/NBC-677\/21\/439) on 9th Sep 2021.This study was registered on clinicaltrials.gov (NCT04943588) on June 29, 2021.At enrollment, written informed consent will be obtained from all eligible participants after explaining details of the study and available treatment options and this will be confirmed by an independent witness.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MAA, is supported by Sir Henry Dale Fellowship jointly funded by the Royal Society and Wellcome Trust (220171\/Z\/20\/Z). EB, has received consultancy fees from Roche, AstraZeneca and Vaccitech. PV, has received unrestricted research funding from Gilead that is unrelated to this study. GRF, has received consultancy and speaker fees from Abbvie, Biomarin, CSL Behring, GSK, Gilead and Pfizer. None of the other authors have any competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2529"}}